Overview of Long-term Follow-up from MonumenTAL-1
Focusing on the MonumenTAL-1 study, Mary Steinbach, APRN, provides clinical insights on nail, skin, and oral toxicities associated with talquetamab.
GPRC5D Therapy: Unique Challenges in Adverse Event Management
Lisa Hwa, APRN, DNP, CNP, FAPO, describes the unique challenges in managing adverse events associated with GPRC5D therapy compared with other bispecifics.
Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS
September 10th 2024Experts explain the administration of step-up and treatment doses for GPRC5D at your institution, including whether they are given in clinic or in the community, and will discuss how patients are monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during the step-up phase.
Managing GPRC5D Therapy: Unique AE Challenges and Patient Preparation
September 3rd 2024Experts address the unique challenges in managing adverse events associated with GPRC5D therapies compared to other cancer treatments, while Samantha will discuss strategies for preparing and educating patients undergoing GPRC5D therapy.
Adverse Event Management with BCMA Therapy
Ellen Marin, PA-C, provides an overview of adverse effects associated with BCMA-directed bispecific therapy in multiple myeloma.
Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
A panel of experts on multiple myeloma discuss long-term follow-up data from the MajesTEC-1 and MagnetisMM-3 clinical trials.